Three-Year-Old’s Metastatic Hepatoblastoma Reportedly Vanishes After Experimental CAR T-Cell Therapy
On November 22, 2026, [themorning.science reported] that a three-year-old’s metastatic cancer reportedly vanished after two doses of an experimental therapy.
Solid tumors have long resisted CAR T cell therapy, yet a young patient experienced a complete regression of hepatoblastoma following the outpatient treatment, Yahoo reported. While conventional immunotherapy typically targets blood cancers, this case shows that genetically engineered immune cells can successfully clear resistant liver cancer that has spread to the lungs. According to ScienceAlert, the therapy’s success in this instance marks a notable development in pediatric oncology research.
Before receiving the experimental GPC3-CAR treatment, the boy underwent three rounds of chemotherapy, primary tumor removal surgery, and two lung operations, Yahoo reported. When first diagnosed, the patient had a liver mass measuring 11.2 cm by 9.6 cm by 7.1 cm. The cancer had metastasized to his lungs with indications of spread to his bones. The cancer quickly returned in his lungs, prompting his enrollment in the CARE study.
“This case demonstrates that a durable complete response in a chemotherapy-resistant solid tumor can be achieved entirely in the outpatient setting without systemic toxicity,” said first author and pediatric oncologist David Steffin from the Baylor College of Medicine in Houston, Texas, Yahoo reported.
The experimental therapy utilized the patient’s own T cells, engineered to recognize the glypican-3 protein expressed in liver cancers, Yahoo reported. Researchers also added genes for interleukin-15 and interleukin-21 to enhance tumor-killing persistence, drawing on previous evidence from preclinical models. Following the initial infusion, the patient exhibited a partial response, evidenced by falling levels of alpha-fetoprotein in his blood.
After a second dose administered eight weeks following the first infusion, follow-up scans revealed no remaining disease outside of residual scarring, Yahoo reported. Findings from The New England Journal of Medicine detail that the patient remained disease-free twelve months later.
“This study provides evidence that these novel CAR T cells may be a safe and effective modality for hepatoblastoma and highlights the need for further assessment in patients with GPC3+ solid tumors,” said co-author and pediatric oncologist Andras Heczey from Seattle Children’s Hospital and the University of Washington, Yahoo reported.
Clinical evaluation of the approach continues through both the CARE study at Baylor College of Medicine and the IMPACT trial at Seattle Children’s Hospital, Yahoo reported. However, themorning.science said that a single reported case does not establish broad effectiveness across other patients. Researchers acknowledge the potential significance of the findings, noting that liver cancer remains the third leading cause of cancer-related death globally.